MSU-42011

Modify Date: 2025-08-23 15:30:00

MSU-42011 structure	Common Name	MSU-42011
	CAS Number	2456434-36-7	Molecular Weight	382.54
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₃₄N₂O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of MSU-42011

MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the expression of iNOS and p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity. MSU-42011 can be used for cancer research[1].

Name	MSU-42011

Description	MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the expression of iNOS and p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity. MSU-42011 can be used for cancer research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> NO Synthase Signaling Pathways >> Cell Cycle/DNA Damage >> PERK Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR
References	[1]. Moerland JA, et al. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Sci Rep. 2020 Dec 17;10(1):22244. [2]. Leal AS, et al. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel). 2021 Oct 6;13(19):5004.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> NO Synthase

Signaling Pathways >> Cell Cycle/DNA Damage >> PERK

Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR

References

[1]. Moerland JA, et al. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Sci Rep. 2020 Dec 17;10(1):22244.

[2]. Leal AS, et al. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel). 2021 Oct 6;13(19):5004.